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Abstract: Pancreatic cancer is one of the most aggressive tumor entities. Diffuse metastatic infiltration
of vessels and the peritoneum restricts curative surgery. Standard chemotherapy protocols include
the cytostatic drug gemcitabine with limited efficacy at considerable toxicity. In search of a more
effective and less toxic treatment modality, we tested in human pancreatic cancer cells (MiaPaca
and PaTuS) a novel combination therapy consisting of cytostatic drugs (gemcitabine or cisplatin)
and gas plasma-conditioned Ringer’s lactate that acts via reactive oxygen species. A decrease in
metabolic activity and viability, change in morphology, and cell cycle arrest was observed in vitro.
The combination treatment was found to be additively toxic. The findings were validated utilizing
an in ovo tumor model of solid pancreatic tumors growing on the chorion-allantois membrane of
fertilized chicken eggs (TUM-CAM). The combination of the drugs (especially cisplatin) with the
plasma-conditioned liquid significantly enhanced the anti-cancer effects, resulting in the induction of
cell death, cell cycle arrest, and inhibition of cell growth with both of the cell lines tested. In conclusion,
our novel combination approach may be a promising new avenue to increase the tolerability and
efficacy of locally applied chemotherapeutic in diffuse metastatic peritoneal carcinomatosis of
the pancreas.
Keywords: anticancer drugs; combination therapy; kINPen; plasma medicine; reactive oxygen and
nitrogen species; ROS
1. Introduction
With approximately 18.1 million new cases diagnosed and about 9.6 million deaths in 2018, cancer
is one of the most significant global medical challenges of our time [1]. It represents the most common
cause of death in the western world within the younger population below the age of 80 [2]. Numerous
improvements in the diagnosis and treatment of cancer, notwithstanding, pancreatic cancer (PC)
remains one of the most lethal cancers with an almost equally incidence and mortality [3]. Due to
non-specific symptoms in the early stages of the disease, the diagnosis is often made late in patients
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already suffering from advanced metastatic disease [4]. Even with advanced surgery (e.g., vessel
reconstruction and neoadjuvant chemotherapy), only about a quarter of patients are suitable for
curative surgery [5,6]. With maximal surgery and adjuvant chemotherapy (chemotherapy = CTx),
the five-year survival rate is nonetheless unsatisfactorily low with 17.5–28.8% [7,8]. In addition,
the incidence of PC is on the rise, and by 2030, it is expected to be the second most common cause of
cancer-related deaths [9].
Due to the unsatisfactory clinical results, new therapeutic approaches are urgently needed.
The combination of chemotherapeutics with reactive oxygen species (ROS) or ROS-producing drugs
has long been debated as an exciting approach in cancer therapy [10]. Among the technical approach
to locally generate ROS is photodynamic therapy, mainly generating singlet oxygen [11], and laser
treatment of pancreatic cancer. The laser treatment does produce significant anticancer effects; however,
it is unpractical in its clinical application [12]. Another option to generate multiple ROS is the
application of cold physical plasma. Not to be confused with blood plasma, gas plasmas are electrically
neutral gases that can be generated at tissue-compatible temperatures of about 40 ◦C. As a result of the
(partial) ionization, ambient air serves as a reservoir to generate vast amounts of ROS [13].
Several groups, including us, have previously demonstrated anti-tumor effects with physical
plasma treatment [14–16]. Some studies already highlighted an added value when combining direct
plasma treatment with chemotherapeutic [17–20]. Apart from the possibility of directly treating cells
or tissues, significant efforts have also been undertaken to utilize the therapeutic capacity of liquids
exposed to gas plasmas [21]. While initially, cell culture medium was used predominantly for this
purpose in vitro and even in vivo [22,23], it became increasingly clear that only clinically relevant
liquids such as sodium chloride and Ringer’s lactate harbor the translational potential to improve
therapeutic outcomes in preclinical and clinical models [24]. Ringer’s lactate solution or liquid showed
to be especially promising candidates because central mediators such as hydrogen peroxide (H2O2)
are stable over weeks while the lactate serves as an essential bystander for the anti-cancer effects
observed [25].
Most standard cancer therapies involved one or several oncological treatments based on decades
of clinical experience, i.e., surgery, radiation, immunotherapy/targeted therapy, and chemotherapy.
With ever more combination therapies emerging at the clinical horizon, it seems clear that the value
of plasma-conditioned liquids likely is to serve as an additive compound to existing therapies.
One example is the hyperthermic intraperitoneal chemotherapy (HIPEC), where a chemotherapeutic
agent dissolved into a liquid is perfused in the peritoneal cavity to locally attack metastatic tumor
nodes in conjunction with cytoreductive surgery [26]. There is a great need for increasing efficacy
and decreasing the side effects of this therapy based on the drugs commonly used [27]. To this
end, we investigated the combined effect of plasma-conditioned liquid and the HIPEC drugs
cisplatin and gemcitabine in pancreatic cancer cells in vitro (two-dimensional monolayers) and
in ovo (three-dimensional tumor with blood supply and matrix remodeling). Promising additive
tumor-toxicity was observed that might optimize intraperitoneal perfusion in future therapies of
pancreatic cancers or peritoneal carcinomatosis by reducing drug concentrations and thereby decreasing
side effects while maintaining a similar efficacy.
2. Results
2.1. Cisplatin, Gemcitabine, and Plasma-Conditioned Ringer’s Lactate Inactivated Pancreatic Cancer Cells in a
Dose-Dependent Manner
To test the effect of cisplatin or gemcitabine in combination with physical plasma-conditioned
Ringer’s lactate (RiLac), the first step was to identify the optimal concentration of each compound to
reach a 25% reduction in the cancer cells metabolic activity (IC-25). The metabolic activity of the cells is
analyzed utilizing their capacity to reduce resazurin to the fluorescent resorufin. The transformation of
this metabolite correlates with the cells’ metabolic activity, so it can be used to describe the percentage
of cancer cells that were inactivated through the different treatment regimens [28]. Cisplatin inactivated
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MiaPaca and PaTuS human pancreatic cancer cells in a dose-dependent manner (Figure 1a). The PaTuS
cancer cells were more resistant to both drugs, and to reach the IC-25, 50 µM of cisplatin were needed,
while a similar effect was reached with 25 µM of gemcitabine. The toxic effect of gemcitabine was
detectable at lower concentrations (Figure 1b). As the next step, an oxidative liquid was generated
using cold physical plasma (Figure 1c) using Ringer’s lactate (RiLac). RiLac is a well known and
clinically applied liquid and could already proof in a previous study to be an excellent candidate to
store physical plasma-derived oxidants [24]. The idea was to combine this liquid with chemotherapy
in two ways. The oxidative liquid was applied before chemotherapy to investigate sensitization
to chemotherapy with oxidative stress (plasma-CTx), or chemotherapy was added first to sensitize
cells to oxidative stress (CTx-plasma). One crucial mediator of the effect of plasma-conditioned
liquid is hydrogen peroxide (H2O2) that was deposited in RiLac through the exposure to the effluent
of the kINPen argon-plasma jet in a treatment time-dependent fashion (Figure 1d). Treatment
times of 60 s generated 200 µM of H2O2 while 120 s generated approximately 300 µM. To calculate
reliable values of generated hydrogen peroxide, the amount of evaporated liquid during these long
plasma treatment times was supplemented with double-distilled water (Supplementary Figure S1a).
Besides H2O2, the time-dependent deposition of nitrate and to a greater extent nitrite was detected
in plasma-conditioned RiLac (Figure 1e). The oxidational capacity of the plasma-conditioned RiLac
was validated via oxidation of the hydroxyl radical and peroxynitrite anion indicator hydroxyphenyl
fluorescein (HPF, Figure 1f). Ringer’s lactate is an ideal oxidative solution, it lacks buffer capacity
and long plasma-treatment times could induce a drop in the pH level of the liquid. However, 120 of
the exposure of RiLac to gas plasma only modest decreased the pH, which was also the case for a
combinational regimen with cisplatin and gemcitabine (Figure 1g). MiaPaca cells reached the 25%
reduction of their metabolic activity after exposure to 60 s plasma-conditioned RiLac, while PaTuS
needed 120 s (Figure 1e) to reach the target IC-25. These experiments defined the treatment modalities
that were kept constant throughout all further experiments in this study (Table 1).
2.2. Combination of Cisplatin and Gemcitabine with Physical Plasma-Conditioned Ringer’s Lactate Enhanced
the Inactivation of Pancreatic Cancer Cells
To next identify the benefit of combination therapy, cisplatin or gemcitabine were combined with
physical plasma-conditioned RiLac and compared to the respective single treatment regimens. For this,
cells were exposed to one CTx, plasma-RiLac, or RiLac alone for 30 min before the respective liquid
was removed and exchanged with the cell culture medium. After 24 h of culture, the respective second
treatment was performed, and the cells were now exposed to the complementary treatment as foreseen
in the combination therapy regimen (Figure 2a). The downstream analysis of the cells was performed
24 h after the addition of the second treatment or control condition (i.e., 48 h after exposure to the first
treatment or control condition). Plasma-condition RiLac and CTx alone showed a modest but significant
reduction of the metabolic activity in MiaPaca (Figure 2b) but not PaTuS (Figure 2c) pancreatic cancer
cells. In contrast to these results, the combination of gemcitabine and cisplatin with plasma-RiLac
(in both plasma-CTx and CTx-plasma treatment protocols) induced a significant inactivation of PaTuS
cells (Figure 2c) with cisplatin having a stronger combination effect compared to gemcitabine. This
was also observed in MiaPaca cells that, in general, responded stronger to combination treatment with
CTX and plasma-RiLac (Figure 2b) as compared to the other regimens and PaTuS cells, respectively.
The concentration of hydrogen peroxide was measured in the combinational regimen, showing only
less difference to the mono treatment with plasma-conditioned RiLac, and also in wells that received
fresh plasma-RiLac 30 min before (Figure 2d). This showed a 50% decrease in H2O2 through the reaction
with the cancer cells. In order to gain more knowledge about the vital role of H2O2 in mediating the
cytotoxic effect experiments were carried out were H2O2 was supplemented to RiLac in the same
amount generated through the plasma-treatment. The combinational regimen, containing H2O2 only,
also diminished the cancer cells’ metabolic activity but was less effective (Supplementary Figure S1b,c).
In further control experiments, the H2O2-scavenging enzyme catalase was added to all treatment
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regimens and completely diminished the effect of plasma-conditioned RiLac, validating the critical
role of H2O2 for the plasma effect (Supplementary Figure S1d–g). Interestingly, the scavenging could
not fully prevent the effect when plasma-conditioned RiLac was applied in combination with CTx.
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Figure 1. Dose-depended inactivation of pancreatic cancer cells through the application of cisplatin,
gemcitabine, or physical plasma-conditioned Ringer’s lactate. (a,b) the metabolic activity of MiaPaca
and PaTuS pancreatic cancer cells 24 h post-exposure to (a) cisplatin and (b) gemcitabine IC-25 target-line
(green); (c) schematic overview of the standardized exposure of 100 µL Ringer’s lactate to the effluent
of a kINPen argon plasma jet for 0, 15, 30, 60, and 120 s, and (d) the amount of hydrogen peroxide
(H2O2) generated in this liquid; (e) metabolic activity of MiaPaca and PaTuS pancreatic cancer cells 24 h
post-exposure to the respective physical plasma-conditioned Ringer’s lactate. Data are (a,b) mean ± SD
and are representatives out of three independent experiments, (d) individual technical replicates with
curve fitting of a quadratic function (R2 = 0.992) from three technical replicates; (e) concentration of
nitrate and nitrite in plasma-conditioned liquid; (f) oxidation of hydroxyphenyl fluorescein (HPF) in
Ringer’s lactate through 120 s of plasma-treatment; (g) pH value of 120 s plasma-conditioned Ringer’s
lactate and plasma in combination with cisplatin and gemcitabine; (h) metabolic activity of pancreatic
cancer cells with IC-25 target-line (green) 24 h post-exposure to physical plasma-conditioned Ringer’s
lactate as representative out of three independent experiments showing median and min to max.
Statistical significance was calculated utilizing ANOVA.
Table 1. Concentration of adjuvant chemotherapy (CTx) and plasma-conditioned Ringer’s lactate used
in this study.
Drug Concentrations or Plasma-Exposure Times to 100 µL of Treatment Liquid for in vitro and in ovo
Experiments to Reach at Least IC-25
Component Cisplatin Gemcitabine Plasma-conditioned Ringer’s Lactate
MiaPaca 25 µM 50 µM 60 s/100 µL
PaTuS 50 µM 50 µM 120 s/100 µL
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2.3. Combination of Cisplatin and Gemcitabine with Physical Plasma-Conditioned Ringer’s Lactate Mediated
Terminal Cell Death to Pancreatic Cancer Cells
To analyze whether the decrease in metabolic activity was concomitant with terminal cell death,
cells were harvested after control, single, or combination treatment at 48 h. Using DAPI as nuclear
counterstain allowing the identification of cells with compromised cellular membranes, and a dye
identifying the presence of active caspases within cells, it was possible to distinguish between viable
(DAPI−, caspase−), early apoptotic (DAPI−, caspase+), late apoptotic (DAPI+, caspase+) and necrotic
(DAPI+, caspase−) MiaPaca (Figure 3a) and PaTuS (Figure 3b) cells. All treatment regimen reduced
the viability of the MiaPaca (Figure 3c) and PaTuS (Figure 3d) cells. The single-agent treatment
regimens only modestly reduced the fraction of viable cells, while the reduction was much greater with
combination treatment in both cell lines. The most effective regimen in PaTuS was plasma-cisplatin
(viability = 76.3%) and cisplatin-plasma (83.3%) followed by gemcitabine-plasma (viability = 76.4%)
and plasma-gemcitabine (78.8%) (Figure 3d). In general, responses in MiaPaca cells were greater with
plasma-cisplatin (viability = 31.4%) or cisplatin-plasma (37.6%) (Figure 3c). The combination with
gemcitabine was weaker compared to that of cisplatin in MiaPaca cells with viability decreasing to
64.7% with plasma-CTx, followed by CTx-plasma.
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Figure 3. Co bination of cisplatin and ge citabine ith physical plas a-conditioned Ringer’s lactate
induced toxicity in pancreatic cancer cells. (a,b) representative gating of viable (DAPI-, caspase-),
early apoptotic (DAPI-, caspase+), late apoptotic (DAPI+, caspase+) and necrotic (DAPI+, caspase-)
MiaPaca (a) or PaTuS (b) cells at 48 h after exposure to plasma-CTx, CTx-plasma, or the corresponding
Ringer’s lactate control (RiLac); (c,d) quantification of the percentage of viable, early and late apoptotic,
or necrotic cells at 48 h for (c) MiaPaca and (d) PaTuS pancreatic cancer cells. Data are presented as
mean and ar representatives out of three independent experiments.
2.4. Combination Therapy Induced orphological Alterations and Cell Cycle Arrest in Pancreatic Cancer Cells
To further investigate the additive toxicity of the combination treatment on the pancreatic cancer
cells, we performed quantitative high content image analysis on several cellular and morphological
parameters (Figure 4a,b). To confirm cytotoxicity by fluorescence microscopy, exposing MiaPaca cells
to cisplatin first and plasma-conditioned RiLac second led to a substantial and significant elevation
of the percentage of dead cells (DAPI+/all cell events) (Figure 4c). For all other treatment regimens,
cytotoxic responses were observed in tendency. Moreover, the total growth area of MiaPaca cells was
also affected by the different treatment regimens at 48 h post initial exposure. In comparison to the
RiLac control, both plasma-cisplatin and cisplatin-plasma and also cisplatin alone induced significant
growth retardation (Figure 4d). A similar trend was observed when using gemcitabine. The altered cell
gro th features were accompanied by morphological changes. Individual MiaPaca cells exposed to
cisplatin-plasma had an increased area per cell indicative of cellular swelling (Figure 4e). The swelling
was also observed with the combination treatment using gemcitabine. As a second morphological
feature, the individual cell’s roundness significantly decreased in all combination treatment regimens
in MiaPaca cells (Figure 4f). PaTuS cancer cells grow in larger aggregates, requiring different algorithms
and quantitative techniques to investigate changes by microscopy. Cell death per growth area was
calculated (DAPI+/area), and similarly to MiaPaca cells, cisplatin-plasma significantly increased toxicity
in PaTuS cells (Figure 4g). Analyzing the growth characteristics of PaTuS cells following the different
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Figure 4. A combination of cisplatin and gemcitabine with physical plasma-conditioned Ringer’s lactate
was toxic, reduced the cancer cells’ growth, and altered their morphology. (a) Representative images
with the DAPI fluorescence channel and digital phase contrast of MiaPaca cells (scale-bar = 50 µm);
(b) representative images with the DAPI fluorescence channel and digital phase contrast of PaTuS cell
(scale-bar = 50 µm); (c–f) algorithm-based quantification of high-content imaging experiments showing
(c) the toxicity (% DAPI+ events on all events), (d) the growth area (area of the pseudo-cytosolic digital
hase contrast), (e) the area per cell, and (f) and roundness of MiaPaca pancreatic cancer cells; (g,h)
algorithm-b sed quantification f (g) cell death (DAPI+ events per area) and (h) cell segment tion
rea of tr ated PaTuS cells. Imaging was perform d at 48 h post initial exposure to t e treatment
liquids. Data are pres tative out of three independent experiments and ar pres ted as (c,g) boxplot
with their median ± min and max, or (e–h) as mean + SEM. Statistical signific ce was calculated
utilizing ANOVA.
iff rent growth properties and morph logical alterations can be indicative of cellular senescence
that is i duced by an arrest of the cell cycle. To address this question, the cont nt of ucleic acid
inside the cells was qu ntified by flow cytometry, and the ra io of cells in the G2 over the G1 phase
was calculated. Th singl treatment with physical plasma-conditi ed RiLac introduced the most
dra ic changes i cell cycle arrest, except for the treatment with plasma-cisplatin in MiaPaca cells
(Figure 5a–h). However, also drug mono treatment ( xcept gemcitabine in MiaPaca cells) elevate th
number of the cells stuck in the G2 fraction. In addition, all c mbinati n therapies, with the exception
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2.5. Drug Concentrations in Pancreatic Cancer Cells Changed in Combination Treatment as Analyzed Using
Mass Spectrometry
Next, we asked whether the exposition to plasma-conditioned RiLac alters the drug uptake and
hence, the intracellular concentration of chemotherapeutic agents. To distinguish between acute
effects, e.g., higher membrane penetrability (short-term), and prolonged effects, e.g., differences in
expression or function of membrane transporter (long-term), the second treatment was performed
with a latency of either 30 min or 24 h. First, it was found that the intracellular drug levels were
higher in MiaPaca compared to PaTuS cells (Figure 6a–d). Secondly, short-term concentrations were
always higher than long-term concentrations. Third, intracellular levels of cisplatin were generally
above those of gemcitabine. These findings directly correlate with the toxic effects that were observed
in our cytotoxicity studies. Plasma-treated RiLac reduced intracellular drug levels in MiaPaca cells,
regardless of the sequence of combination therapy. For PaTuS, a similar effect was observed in
the short-term conditions, while long-term conditions showed roughly equal levels in mono and
combination treatments. This points to altered drug uptake or efflux from pancreatic cancer cells
exposed to plasma-treated RiLac.
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2.6. Combination Treatment Abrogated Cancer Growth in an in Ovo 3D-Tumor Model
To validate our findings in a more realistic model, MiaPaca and PaTuS pancreatic cancer cells
were seeded on the chorion allantois membrane of fertilized chicken eggs (TUM-CAM model).
This model allows for the growth of three-dimensional tumors (Figure 7a). While these tumors are
void of immune cells, they become vascularized to form solid 3D-tumors. Treatment regimens were
RiLac alone, plasma-conditioned RiLac, cisplatin alone, or cisplatin in combination with physical
plasma-conditioned RiLac. All treatments were applied twice. It was waived to use gemcitabine
in a combinational regimen on this in ovo model because cisplatin was identified to be the most
promising candidate. The tumors were explanted 48 h after initial exposure to the liquids and weighted.
For MiaPaca tumors, all treatment regimen significantly reduced the tumors mass compared to the
RiLac control (93.3 ± 8.8 mg) (Figure 7b). Most tremendous changes were observed for the combination
treatment with cisplatin and plasma that reduced the tumor mass to 52.9 mg (± 5.6 mg), which was
significantly lower than the cisplatin (65.2 ± 9.1 mg) and control (76.8 ± 6.6 mg) treatment (Figure 7b).
Control PaTuS tumors were 105.3 mg (± 38.6 mg). Combination treatment significantly retarded tumor
growth to 49.8 mg (± 17.9 mg). Cisplatin treatment gave 92.3 mg (± 29.2 mg), while plasma-treated
RiLac achieved a significant reduction to 62.1 mg (± 28.6 mg) (Figure 7c). The ability to induce
apoptosis is a crucial factor in the evaluation of oncologic strategies. Therefore, we examined the
tumors by immunofluorescence for apoptosis by quantifying the amount of TUNEL+ cells over all
cells (TUNEL+/DRAQ5+). In MiaPaca tumors, spontaneous apoptosis was a rare event (0.6 ± 0.7%).
Treatment with plasma (19.2 ± 9.7%) or cisplatin (26.2 ± 4.6%) significantly increased the rate of
apoptotic cells. Combination treatment gave the strongest apoptotic response (38.8 ± 12.1%) (Figure 7e).
Next, we quantified the distance of apoptotic cells from the outer tumor layer and found a mean
activity depth of 423 µm (± 100 µm) with cisplatin (Figure 7f). However, both, plasma (851 ± 203.4 µm)
and the combination treatment (1003 ± 222 µm) significantly showed significantly deeper penetration
into the tissue (Figure 7f). In PaTuS tumors, spontaneous apoptosis was observed in 4.3% (± 5.9%)
of the tumor cells. However, treatment with plasma (20.0 ± 5.8%) or cisplatin (32.4 ± 12.7%) alone,
as well as the combination (37.2 ± 17.9%), significantly increased the rate of apoptosis (Figure 7h).
By contrast, differences in penetration depth were not observed (Figure 7i). Furthermore, the percentage
of proliferating (Ki-67+) cells was calculated. Tumors that received plasma-conditioned RiLac showed
decreased proliferation in tendency, but differences were minor with all groups compared to the RiLac
control (Supplementary Figure S1h,i).
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3. Discussion
Most protocols in adjuvant, additive, and palliative CTx for PC are based on gemcitabine either
as monotherapy or in combination with, for instance, capecitabine (ESPAC-4 [7]). Despite a better
understanding of the pathogenesis of PC, the prognosis has improved only slightly in absolute terms.
The best survival rates are observed in resected patients, with a median survival between 13 and
48 months, depending mainly on the tumor stage (i.e., T1/2 or T3/4) [7,8,29]. In metastatic non-resectable
pancreatic cancer, median survival is between 5–7.5 months on palliative chemotherapy [30,31]. In this
context, best survival rates (11 months) were observed using FOLFIRINOX, a gemcitabine-free scheme;
however, its application is limited to those patients in good condition [32]. Therefore, gemcitabine is
still the standard for most patients suffering from pancreatic PC.
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Nevertheless, and mainly due to the unsatisfactory results of chemotherapy, various
pharmacological combination treatment schemes have been investigated in recent years, with usually
only a slightly positive effect on survival coming at the costs of a significant increase in treatment-related
toxicity [33]. One combination scheme involves gemcitabine and cisplatin, as used in biliary tract
cancer [34], bladder carcinoma [35], or bronchial carcinoma [36]. This combination was also analyzed
for PC and showed promising results with significantly improved six-month survival and better
tumor response. However, no better overall survival could be demonstrated, and the incidence
of CTx-related complications was also significantly increased compared to mono-treatment with
gemcitabine alone [37].
After transfer into the cell, cisplatin forms adducts with the DNA, and as a consequence, a complex
pathway of apoptotic and survival signaling is initiated [38]. Inactivation of cisplatin by intracellular
scavengers (e.g., glutathione and metallothionein) is considered to be part of the drug resistance acquired
during CTx [39]. Several studies investigated phytochemicals and their potential for sensitizing cancer
cells for cisplatin-based CTx [40]. For example, shikonin, a product of a traditional Chinese medicinal
plant, increased intracellular ROS concentration in vitro and in vivo and, therefore, enhanced cisplatin
toxicity and notably raised selectivity [41].
It has been demonstrated multiple times that cold physical plasma applied either directly or via
conditioned liquid acts as an anticancer agent in vitro [42–45]. Most studies highlight the prominent
role of ROS and RNS, as the effects could be abolished by antioxidant scavengers [46]. Due to their
high reactivity and usually short half-life, it is challenging to trace single reactive species in liquids
or cells and estimate their contribution to biological effects [47–49]. In vivo, however, the previously
promising in vitro results of plasma-conditioned liquids were reproduced in peritoneal metastatic
tumors (gastric cancer [23], ovarian cancer [50], pancreatic cancer [22,51]), recently. These results
raise hopes to integrate plasma medicine into modern, multimodal tumor therapies, mainly since the
restoration of chemoresistance was observed in glioblastoma cells [18].
Surprisingly, there is little evidence of synergism between plasma treatment and CTx in pancreatic
cancer yet. We previously demonstrated an additive effect with gemcitabine and plasma treatment
in murine pancreatic cancer cells without additional harm to non-malignant fibroblasts [52]. In vivo,
a significant tumor reduction in a murine, orthotopic pancreatic cancer model by the combination
of plasma and gemcitabine was observed before [17]. It was also demonstrated that the sequence of
administration of plasma and tegafur (a 5-FU prodrug) plays a decisive role between synergism and
antagonism [53]. However, these studies were performed with direct plasma treatment and possibly
included effects by gas, e.g., plasma-derived electromagnetic fields or UV-radiation. In our current study,
we found an additive toxicity of plasma-conditioned RiLac with chemotherapy. This combination
therapy was superior to mono-treatment in both cell lines investigated, as demonstrated by reduced
metabolic activity and cell viability, and enhanced apoptosis and cell cycle arrest. Additionally,
we demonstrated a significant improvement of the anti-cancer capacity of either cisplatin or
plasma-conditioned RiLac in an in ovo TUM-CAM model by adding the other modality, respectively.
The first barrier clinically applied substances have to overcome is the cell membrane. ROS/RNS
can penetrate or interact with this membrane, as well as use ubiquitous aquaporin channels, whereas
cisplatin and gemcitabine enter the cell via different membrane transporters [54–57]. We hypothesized
that plasma-conditioned liquid sensitizes the tumor cell for subsequent CTx via oxidative stress
induction. By contrast, we found the intracellular concentration of cisplatin and gemcitabine being
reduced in cells conditioned with plasma-treated RiLac. As a possible explanation, we hypothesize
that cells exposed to plasma-conditioned RiLac experience oxidative stressed and became inactivated.
Hence, the lower levels might have been due to reduced transporter activity in the short-term samples,
and an increased portion of terminally dead cells (that nonetheless were still part of the cell pellet
investigated by mass spectrometry) with the long-term samples. This hypothesis is supported by the
reduction in the metabolic activity of the cells and by other hallmarks of cellular senescence. One of
them is the cellular swelling (increased area per cell) that was observed to the greatest extent in our
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combinational regimen [58–60]. Moreover, cell cycle arrest was also observed in the groups that
received the plasma-conditioned RiLac, similarly to our previous observations in colorectal cancer
cells that had received plasma-conditioned saline [42].
With both cell lines investigated, gemcitabine was inferior compared to cisplatin in terms of
cytotoxicity. The combination with plasma-conditioned RiLac was also less effective than that with
cisplatin. This may be due to the mechanism of action of gemcitabine, which relies primarily on
incorporation into the DNA. However, as we have been able to demonstrate, the plasma treatment leads
to a significant increase in cells in the G2 phase, so Gemcitabine is correspondingly less incorporated.
In contrast, plasma-derived radicals or cisplatin could reduce the antioxidant capacity of the cell so
that the vice versa treatment was correspondingly more effective. This might point towards a more
synergistic effect from plasma-conditioned RiLac and cisplatin.
The combination of plasma-conditioned RiLac and CTx was effective in vitro and in ovo.
Applications of cytostatic drugs diluted in plasma-conditioned oxidative liquids (such as RiLac)
therefore hold promising potential in, e.g., postoperative lavage or HIPEC. From our previous studies
using intraperitoneal injections of plasma-conditioned sodium chloride or cell culture medium in
mice, we know that plasma-conditioned liquids did not have any observable side effects [22,42].
Especially plasma-conditioned RiLac was previously demonstrated to have a potent anti-tumor
capacity [61–63]. This was true in vitro and in vivo, and the lactate in RiLac was demonstrated being
essential in mediating toxic effects [25,64]. These studies support our findings and hypothesis of
such an oxidative liquid being suitable for future clinical applications in combination with standard
chemotherapeutics (as cisplatin and gemcitabine) to reduce tumor burden in patients that suffer from,
e.g., pancreatic cancer.
4. Materials and Methods
4.1. Cell Lines and Cultivation
Human pancreatic adenocarcinoma cell lines MiaPaca (MIA PaCa-2; ATCC, Manassas, VA, USA)
and PaTuS (PaTu-8988s; DSMZ, Braunschweig, Germany) were used. Cells were maintained in cell
culture medium (Dulbecco’s modified Eagle’s medium: DMEM GlutaMAX; Gibco ThermoFisher
Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum, 100 U/mL of penicillin, and
100 µg/mL of streptomycin (all Sigma, Steinheim, Germany). The confluence of cells was controlled via
microscopy, and subculturing was performed twice a week, while the passages of the cells were kept
below ten. Incubation took place in a cell culture incubator (Binder, Tuttlingen, Germany) at 37 ◦C
and 5% CO2 under humidified conditions. Possible mycoplasma contamination of the cell culture
was excluded regularly. For the experimental in vitro procedures, the cells were counted using an
acoustic-focussing flow cytometer (Attune NxT, ThermoFisher Scientific) and added at a concentration
of 1 × 104 cells in 100 µL medium per well in 96-well plates. Alternatively, 1 × 105 cells were seeded in
1000 µL medium in 24-well flatbottom plates (Eppendorf, Hamburg, Germany) for flow cytometry
experiments. The therapeutic liquids were scaled up 10× in this setting. Both plate types provide a
rim that can be filled with double-distilled water, to prevent excessive evaporation of the cell culture
medium in the edge wells.
4.2. Physical Plasma and Chemotherapeutic Agents
Cold physical plasma was generated by the atmospheric pressure argon-plasma jet kINPen (neoplas
tools GmbH, Greifswald, Germany), operated at 1.9–3.2 W and 1.1 MHz, and CE-certified as a medical
device class IIa in 2013 [65]. The plasma jet consists of a power supply unit and a handpiece. The latter
contains a rod-shaped electrode that excites the argon gas (purity: 99.999%; Air Liquide, Paris, France).
Outwardly, the device is shielded by a dielectric capillary. For the plasma-treatment of Ringer’s lactate
(RiLac; Hartmann B. Braun, Melsungen, Germany), 100 µL of the liquid was exposed to the plasma
of the device running at two standard liters per minute (2 slm). The visible plasma effluent did not
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directly discharge to the liquid. The distance of the liquid surface to the nozzle (9 mm) as well as
treatment times regulated with high precision utilizing a computer-controlled xyz-table (CNC step,
Geldern, Germany). Immediately after the plasma-conditioning, the plasma-RiLac was transferred to
the plate, harboring the pancreatic cancer cells with just priorily aspirated cell culture supernatant.
Treatment agents were left for 30 min before replacing them with fresh culture medium. For the
detection of H2O2 in the RiLac, the Amplex UltraRed Assay (ThermoFisher Scientific), and for the
detection of nitrate in nitrite, the Griess assay (Cayman Chemical, Ann Arbor, MI, USA) was utilized
according to the manufacturers’ instructions. The chemotherapeutic agents cisplatin (1 mg/mL, Teva,
Petach Tikwa, Israel) and gemcitabine (1 mg/mL, provided by the University Pharmacy Greifswald,
Greifswald, Germany) were stored for a maximum of four weeks at room temperature and protected
from light. Following long plasma exposure times, the amount of evaporated liquid was measured
via a precision balance (Sartorius, Göttingen, Germany) and was supplemented with double distilled
water. Standard dilutions (Table 1) were done in RiLac, and the cells were exposed to the drugs
in a similar regimen as for the plasma-RiLac. Oxidation of the hydroxyl radical and peroxynitrite
anion indicator hydroxyphenyl fluorescein (HPF, ThermoFisher Scientific) was measured immediately
after the treatment of 5 µM of the probe after 120 s of plasma-exposure at the λex = 460–490 nm
and λem = 500–550 nm fluorescence channel of a high content imager (Operetta CLS, PerkinElmer,
Hamburg, Germany). Measurements of the pH were performed with a pH meter (Mettler Toledo,
Columbus, OH, USA).
4.3. Metabolic Activity Detection
To asses the metabolic activity of the cancer cells after treatment, they were exposed to
7-hydroxy-3H-phenoxazin-3-on-10-oxid (resazurin, Alfa Aesar, Haverhill, MA, USA) at 20 h. The dye
can be metabolized by viable cells to generate fluorescent resorufin. Fluorescence was measured after
4 h utilizing a multiplate reader (Tecan F200, Tecan, Männedorf, Switzerland) at λex = 560 nm and
λem = 590 nm. The H2O2 scavenging enzyme catalase (Sigma, Steinheim, Germany) was added at
concentrations of 20 µg/mL in some control experiments prior to addition of plasma-conditioned liquid.
4.4. Flow cytometry
After incubation, cells were washed with phosphate-buffered saline (PBS; PAN Biotech, Aidenbach,
Germany) and detached with accutase (BioLegend, San Diego, CA, USA) containing DAPI (BioLegend)
and Caspase 3/7 Green Detection Reagent (ThermoFisher Scientific). The cells were stained for 30 min
at 37 ◦C before washing twice with PBS. Data acquisition was performed with a CytoFLEX S flow
cytometer (Beckman-Coulter, Brea, CA, USA). For each of the replicates, 10,000 single cells were
acquired and analyzed using Kaluza 2.1 analysis software (Beckman-Coulter). For cell cycle analysis,
cells were harvested and then incubated with ice-cold ethanol at −20 ◦C for 1 h. After washing and
staining with DAPI, flow cytometry data were analyzed for cell cycle phases using the Michael H.
Fox algorithm that is provided within the Kaluza software.
4.5. High Content Imaging
Imaging was performed using a high content imager (Operetta CLS). The device operates a
high-speed motorized table. Images were acquired using a 20x air objective (NA = 0.4; Zeiss,
Jena, Germany) and a 16-bit sCMOS camera with laser-based autofocus. Cells were stained with
DAPI in images in the brightfield, digital-phase contrast (DPC), and the λex = 535–585 nm and
λem = 430–500 nm fluorescence channels were acquired. Image acquisition settings were kept constant.
For each independent experiment, four technical replicates with a total of 36 fields of views per
condition and experiment were imaged. For the quantification of cell counts, cell area, and morphology,
an algorithm-based analysis was performed using Harmony 4.9 image acquisition and quantification
software (PerkinElmer, Hamburg, Germany) after segmenting individual cells via their pseudo-cytosolic
DPC signal.
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4.6. Quantitative Assay for Cisplatin and Gemcitabine
Cisplatin and gemcitabine were quantified in cell pellets after lysis and homogenization of
the cells and protein precipitation by adding 500 µL acetonitrile and subsequent centrifugation
for 5 min at 14,000 g and 4 ◦C. Ten microliters of the clear supernatant were subjected to liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The analysis was performed with
the Agilent 1290 series HPLC system (Agilent Technologies, Waldbronn, Germany) coupled with
the QTRAP5500 mass spectrometer (Sciex, Darmstadt, Germany). Chromatography was performed
using the analytical column Atlantis® HILIC Silica column, 2.1 × 100 mm (Waters, Milford, CT, USA)
by gradient elution with acetonitrile (A) and 0.1% formic acid (B) as mobile phases at a flow rate of
250 µL/min. The applied gradient was as follows: 0–1 min, 99% A; 1–1.1 min, 30% A; 1.1–3 min 30% A;
3–3.1 min 99% A; and 3.1–8 min 99% A. The MS/MS analysis was done in the positive multiple reaction
monitoring mode by considering the following mass-to-charge transitions (and collision energies):
302.0/246.0 (12 eV), 302.0/266.0 (20 eV) and 302.0/210.0 (36 eV) for cisplatin and 246.2/111.6 (23 eV),
246.2/95 (60 eV) and 246.2/69 (55 eV) for gemcitabine. The analytical range of the quantitative method
for both compounds was between 1–100 ng/mL. During the period of sample analysis, the accuracy of
the method was ± 15% (relative error of the nominal values).
4.7. Tumor-Chorion-Allantoic Membrane Model (TUM-CAM)
The chorion-allantois membrane tumor model (TUM-CAM) was performed as described in
previous studies [66,67]. Briefly, pathogen-free eggs (Valo BioMedia, Osterholz-Scharmbeck, Germany)
were incubated for one week at a specialized egg incubator with turning functions (Hemel, Verl,
Germany) at 37.5 ◦C and 65% humidity. On day eight, the eggshells were carefully opened, and a
cell suspension (containing 2 × 106 cells in 50 µL matrigel extracellular matrix components; Corning,
New York, NY, USA) was added to a sterile silicone ring that was placed on the chorion-allantois
membrane (CAM). After a further incubation period of four days, solid tumors with blood vessels
sprouting from the CAM have formed inside the ring. On day 12, the treatment was performed. For this,
the eggs were randomly assigned to groups and received (I) control RiLac, (II) plasma-conditioned
RiLac, (III) cisplatin, or (IV) a combination of plasma-RiLac and cisplatin. RiLac volume was 100 µL of,
and the concentrations of the drugs and plasma are given in Table 1. Following treatment, the eggs
were restored in the breeder, and on the next day, treatment was repeated. On day 14, tumors were
excised and cryo-conservated in liquid nitrogen (−196 ◦C) embedded in freezing medium (Tissue-Tek
O.C.T., Sakura Europe, Alphen aan den Rijn, Netherlands).
4.8. Histology
Ultra-thin sections (5 µm) were cut vertically and mounted on microscope slides. Nuclei were
counterstained using Draq5 (BioLegend). Apoptotic cells were labeled using the TUNEL assay
(In situ cell death detection kit, TMR red; Merck, Darmstadt, Germany) according to manufacturer’s
specifications. Proliferating cells were labeled using an anti-Ki67 monoclonal antibody (primary
antibody: rabbit anti-Ki67; Bethyl Laboratories, Montgomery, TX, USA) that was marked using a
fluorescently labeled secondary antibody (donkey anti-rabbit IgG Brilliant Violet 421; BioLegend)).
Microscopy slides were examined using a Keyence BZ-9000 fluorescence microscope (Keyence,
Frankfurt, Germany). Using the software dynamic cell count (BZ-II Analyser, Keyence, Frankfurt,
Germany), the ratio of TUNEL positive and negative cells (TUNEL+/Draq5+ vs. TUNEL-/Draq5+) was
determined [43].
4.9. Statistical Analysis
Statistical analysis was performed using Prism 8.3 (GraphPad Software, La Jolla, CA, USA).
For statistical comparison between different groups, one-way or two-way analysis of variance
(ANOVA II) with Dunnet’s post-testing was applied. The levels of significance are displayed as asterisks
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in the figures (*, **, or *** for the p-values <0.05, <0.01, or <0.001, respectively). All experiments were
performed at least in three independent runs, and detailed information about the specific number of
replicates as well es the presentation of the data (mean/median, min-max, SD/SEM) is given in the
figure captions.
5. Conclusions
The therapy of pancreatic cancer remains challenging, mainly due to its aggressive and infiltrating
growth, e.g., to the peritoneal cavity. Our data suggest that standard anti-cancer chemotherapies of this
cavity may benefit from a novel combination therapy using pro-oxidative Ringer’s lactate generated
via cold physical plasma. Our approach is elegant and clinically relevant because both the Ringer’s
lactate as well as the kINPen used in this study are clinically certified products theoretically ready
to be used. Further studies are needed using, for instance, tumor materials from patients ex vivo, or
launching individual therapy trials with patients in experimental settings.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/1/123/s1,
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